Key result
Lipoprotein lipase expression marks poor prognosis and supports leukemic cell survival in chronic lymphocytic leukemia.
LPL expression is a key prognostic marker in CLL that reflects a metabolic shift, offering potential insights into new therapeutic avenues targeting lipid metabolism in hematologic malignancies.
Answers are grounded in this paper and cite their sources.
LPL expression may refine CLL prognostication; leaves open whether lipid-metabolism targeting alters outcomes.
Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism. Due to its catalytic activity, LPL is involved in metabolic pathways exploited by various solid and hematologic malignancies to provide an extra energy source to the tumor cell. We and others described a link between the expression of LPL in the tumor cell and a poor clinical outcome of patients suffering Chronic Lymphocytic Leukemia (CLL). This leukemia is characterized by a slow accumulation of mainly quiescent clonal CD5 positive B cells that infiltrates secondary lymphoid organs, bone marrow and peripheral blood. Despite LPL being found to be a reliable molecular marker for CLL prognosis, its functional role and the molecular mechanisms regulating its expression are still matter of debate. Herein we address some of these questions reviewing the current state of the art of LPL research in CLL and providing some insights into where currently unexplored questions may lead to.
No takes yet. Share an insight, caveat, or question.
Prieto et al. (2017) conducted a review in Chronic Lymphocytic Leukemia. Lipoprotein lipase (LPL) expression was evaluated. Lipoprotein lipase expression serves as a robust prognostic marker for poor clinical outcome in chronic lymphocytic leukemia and plays a functional role in leukemic cell survival and metabolic reprogramming.
Synapse has enriched 10 related papers. Consider them for comparative context: